NPM1 and myelodysplastic syndrome: The World Health Organization (WHO) 5th edition classifies AML with mutated NPM1 as a distinct entity, despite the blast count, perhaps due to the rapid time to progression from myelodysplastic syndrome (MDS) or myelodysplastic syndrome/myeloproliferative neoplasm (MDS/MPN) [52].